DarioHealth (NASDAQ:DRIO) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

DarioHealth Corp. (NASDAQ:DRIO) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.71 and traded as low as $0.69. DarioHealth shares last traded at $0.72, with a volume of 55,845 shares trading hands.

Analyst Upgrades and Downgrades

DRIO has been the subject of several research reports. Stifel Nicolaus lowered their target price on DarioHealth from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Litchfield Hills Research assumed coverage on DarioHealth in a report on Monday, May 19th. They set a “buy” rating and a $3.00 price objective for the company.

DarioHealth Price Performance

The firm has a market capitalization of $32.01 million, a price-to-earnings ratio of -0.77 and a beta of 1.58. The company has a quick ratio of 1.32, a current ratio of 1.57 and a debt-to-equity ratio of 0.35. The company’s fifty day moving average is $0.70 and its two-hundred day moving average is $0.71.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). DarioHealth had a negative return on equity of 72.16% and a negative net margin of 205.62%. The company had revenue of $6.75 million during the quarter, compared to the consensus estimate of $7.48 million. During the same quarter in the prior year, the business earned $0.05 earnings per share. Equities research analysts anticipate that DarioHealth Corp. will post -1.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DarioHealth

A hedge fund recently bought a new stake in DarioHealth stock. AMH Equity Ltd acquired a new position in shares of DarioHealth Corp. (NASDAQ:DRIO) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 250,000 shares of the company’s stock, valued at approximately $153,000. AMH Equity Ltd owned about 0.60% of DarioHealth at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.